EUR 14.6
(0.0%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 10.06 Million GBP | 242.93% |
2022 | 2.93 Million GBP | 121.34% |
2021 | 1.32 Million GBP | 1.92% |
2020 | 1.3 Million GBP | -39.26% |
2019 | 2.14 Million GBP | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 Q4 | 10.06 Million GBP | 0.0% |
2023 FY | 10.06 Million GBP | 242.93% |
2023 Q2 | - GBP | -100.0% |
2022 FY | 2.93 Million GBP | 121.34% |
2022 Q4 | 2.93 Million GBP | 0.0% |
2022 Q2 | - GBP | -100.0% |
2021 FY | 1.32 Million GBP | 1.92% |
2021 Q4 | 1.32 Million GBP | 0.0% |
2021 Q2 | - GBP | -100.0% |
2020 Q4 | 1.3 Million GBP | -43.31% |
2020 FY | 1.3 Million GBP | -39.26% |
2020 Q2 | 2.29 Million GBP | 0.0% |
2019 FY | 2.14 Million GBP | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
BioNTech SE | 191 Million EUR | 94.73% |
CureVac N.V. | 36.81 Million EUR | 72.664% |
Biotest Aktiengesellschaft | 377.3 Million EUR | 97.332% |
Biotest Aktiengesellschaft | 377.3 Million EUR | 97.332% |
BRAIN Biotech AG | 25.19 Million EUR | 60.048% |
Formycon AG | 7.81 Million EUR | -28.791% |
Heidelberg Pharma AG | 70.4 Thousand EUR | -14195.454% |
Medigene AG | 2.03 Million EUR | -394.352% |